Henk Mallo

2.1k citations
24 papers · 449 · h-index 12

Impact in

  • Oncology
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
  • Immunology
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

  • Oncology 15
    • Cancer Immunotherapy and Biomarkers 8
    • CAR-T cell therapy research 6
    • Cutaneous Melanoma Detection and Management 2
  • Molecular Biology 9
    • Melanoma and MAPK Pathways 4
    • Protein Degradation and Inhibitors 2
Co-authors
John B.A.G. Haanen (12 shared papers)Gijsbert C. de Gast (4 shared papers)Astrid A.M. van der Veldt (2 shared papers)Epie Boven (2 shared papers)Helgi H. Helgason (2 shared papers)Axel Bex (5 shared papers)Alfons J.M. van den Eertwegh (1 shared paper)Johannes Berkhof (1 shared paper)
Journals
Annals of Oncology (6 papers)Journal of Clinical Oncology (3 papers)Clinical Cancer Research (2 papers)Cancer Immunology Immunotherapy (2 papers)British Journal of Cancer (2 papers)
Partner nations
NetherlandsAustraliaSweden

In The Last Decade

Henk Mallo

22 papers receiving 445 citations

Peers

Henk Mallo
Comparison fields: 5 of 55
  • Oncology 176
  • Immunology 124
  • Pulmonary and Respiratory Medicine 152
  • Ophthalmology 29
  • Cancer Research 41
Replace Georgia Gomatou with:
Georgia Gomatou Greece
Davide Bosso Italy
Amandine Quivy France
Deirdre Kelly Canada
Nethanel Asher Israel
Mazhar Ajaz United Kingdom
Annelieke E.C.A.B. Willemsen Netherlands
J.B.A.G. Haanen Netherlands
V. Guillem Porta Spain
Depei Huang China
Henk Mallo relative to Georgia Gomatou Greece Georgia Gomatou's profile →
Citations per field
00.5×2×4×6×
Georgia Gomatou · 1×
Citations per year

Countries citing papers authored by Henk Mallo

Since Specialization
Citations

This map shows the geographic impact of Henk Mallo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henk Mallo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henk Mallo more than expected).

Fields of papers citing papers by Henk Mallo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henk Mallo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henk Mallo. The network helps show where Henk Mallo may publish in the future.

Co-authors

The 25 scholars most cited alongside Henk Mallo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Henk Mallo Line = papers co-authored together Henk Mallo links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
British Journal of Cancer ·Astrid A.M. van der Veldt, Epie Boven, Helgi H. Helgason, Merian van Wouwe, Johannes Berkhof, Gijsbert C. de Gast, Henk Mallo, C Tillier, Alfons J.M. van den Eertwegh, John B.A.G. Haanen
2008103
2
On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients
Clinical Cancer Research ·Monique van Oijen, Adriaan D. Bins, Sjoerd G. Elias, Johan Sein, P. Weder, Gijsbert C. de Gast, Henk Mallo, M.P.W. Gallee, Harm van Tinteren, Ton N. Schumacher, John B.A.G. Haanen
200441
3
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)
Melanoma Research ·Elisa A. Rozeman, Warner Prevoo, Mark A. Meier, Karolina Sikorska, Trieu My Van, Bart A. van de Wiel, Jacqueline E. van der Wal, Henk Mallo, Lindsay G. Grijpink-Ongering, Annegien Broeks, Ferry Lalezari, Jason Reeves, Sarah Warren, Johannes V. van Thienen, Harm van Tinteren, John B.A.G. Haanen, Ellen Kapiteijn, Christian U. Blank
202039
4
Brain Metastases in Patients With Renal Cell Cancer Receiving New Targeted Treatment
Journal of Clinical Oncology ·Helgi H. Helgason, Henk Mallo, Helga Droogendijk, John Haanen, Astrid A.M. van der Veldt, A.J. van den Eertwegh, Epie Boven
200738
5
T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy
Clinical Cancer Research ·Esther P.M. Tjin, Debby Konijnenberg, Gabrielle Krebbers, Henk Mallo, Jan W. Drijfhout, Kees L. M. C. Franken, Chantal M.A.M. van der Horst, Jan D. Bos, Omgo E. Nieweg, Bin B. R. Kroon, John B.A.G. Haanen, Cornelis J.M. Melief, Florry A. Vyth‐Dreese, Rosalie M. Luiten
201132
6
Determination of Sunitinib and Its Active Metabolite N-Desethylsunitinib in Sweat of a Patient
Journal of Analytical Toxicology ·Nienke A. G. Lankheet, Christian U. Blank, Henk Mallo, S. Adriaansz, Hilde Rosing, J. Schellens, Alwin D. R. Huitema, J. H. Beijnen
201130
7
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
British Journal of Cancer ·Natascha Verra, Slinger Jansen, Gerard Groenewegen, Henk Mallo, Michael Kersten, Axel Bex, Florry A. Vyth‐Dreese, Johan Sein, Willeke van de Kasteele, W J Nooijen, Mirjam de Waal, Simon Horenblas, G C de Gast
200330
8
Interferon alpha 2b as Medical Selection for Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma: A Consecutive Study
European Urology ·Axel Bex, Martÿn Kerst, Henk Mallo, Wim Meinhardt, Simon Horenblas, G. C. de Gast
200527
9
A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor
Cancer Immunology Immunotherapy ·Axel Bex, Henk Mallo, Martijn Kerst, John B.A.G. Haanen, Simon Horenblas, Gijsbert C. de Gast
200420
10
Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients
Journal of Immunotherapy ·Adriaan D. Bins, Henk Mallo, Johan Sein, Colette van den Bogaard, Willem J. Nooijen, Florry A. Vyth‐Dreese, Bastiaan Nuijen, Gijsbert C. de Gast, John B.A.G. Haanen
200719
11
3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
Annals of Oncology ·Christian U. Blank, Judith M. Versluis, ILM Reijers, Karolina Sikorska, Winan J. van Houdt, Johannes V. van Thienen, S. Adriaansz, Henk Mallo, Harm van Tinteren, Bart A. van de Wiel, Lindsay G. Grijpink-Ongering, Annemarie Bruining, John B.A.G. Haanen, Alexander C. J. van Akkooi, Ton N. Schumacher, Elisa A. Rozeman
201912
12
Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study
Supportive Care in Cancer ·Itske Fraterman, Savannah Glaser, Sofie Wilgenhof, Stephanie Medlock, Henk Mallo, Ronald Cornet, Lonneke V. van de Poll‐Franse, Annelies H. Boekhout
202212
13
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study
Cancer Immunology Immunotherapy ·J. Martijn Kerst, Axel Bex, Henk Mallo, L. Dewit, John B.A.G. Haanen, Willem Boogerd, Hendrik J. Teertstra, G C de Gast
200511
14
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
Journal of Clinical Oncology ·Judith M. Versluis, Karolina Sikorska, Elisa A. Rozeman, Alexander M. Menzies, Hanna Eriksson, W. Martin C. Klop, Robyn P.M. Saw, Bart A. van de Wiel, Richard A. Scolyer, Johannes V. van Thienen, Henk Mallo, Maria Gonzalez, Alex Torres Acosta, Lindsay G. Grijpink-Ongering, Anja van der Wal, John B.A.G. Haanen, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long, Christian U. Blank
20228
15
Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra)
Annals of Oncology ·E.A. Rozeman, Karolina Sikorska, Lindsay G. Grijpink-Ongering, Birthe C. Heeres, Bart A. van de Wiel, Ayşegül Sarı, Henk Mallo, S. Adriaansz, Wilma Uyterlinde, J. Lijnsvelt, Loes M. Pronk, J.B.A.G. Haanen, Jan Willem B. de Groot, Sofie Wilgenhof, M.A. Vollenbergh, Johannes V. van Thienen, Christian U. Blank
20187
16
The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome
European Journal of Clinical Pharmacology ·Nienke A. G. Lankheet, Alwin D. R. Huitema, Henk Mallo, S. Adriaansz, John B.A.G. Haanen, Jan H.M. Schellens, Jos H. Beijnen, Christian U. Blank
20136
17
Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma
Annals of Oncology ·Maartje W. Rohaan, Raquel Gomez-Eerland, Marnix H. Geukes Foppen, Maaike van Zon, Renate de Boer, Noor A. M. Bakker, Loes M. Pronk, Ayşegül Sarı, Henk Mallo, Bart A. van de Wiel, Ferry Lalezari, Jos H. Beijnen, Bastiaan Nuijen, Harm van Tinteren, Johannes V. van Thienen, Christian U. Blank, Sofie Wilgenhof, Ton N. Schumacher, Joost H. van den Berg, John B.A.G. Haanen
20196
18
Downsizing of locally advanced stage III (bulky) BRAF V600E/K melanoma with combination targeted therapy to achieve R0 resection
European Journal of Cancer ·J.B.A.G. Haanen, C.U. Blank, H.V. van Thienen, Henk Mallo, S. Adriaansz, Sylvia ter Meulen, Max F. Madu, Loes M. Pronk, Bernies van der Hiel, B. van de Wiel, Daniel S. Peeper, Alexander C. J. van Akkooi
20173
19
Extended Continuous Oral Temozolomide in Patients with Progressive Metastatic Renal Cell Carcinoma Not Responding to Interferon Alpha 2b
Journal of Chemotherapy ·Axel Bex, J. Martijn Kerst, Henk Mallo, Harm van Tinteren, Simon Horenblas, G. C. de Gast
20052
20
1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma
Annals of Oncology ·M.W. Lucas, Elisa A. Rozeman, Judith M. Versluis, Alexander M. Menzies, Hanna Eriksson, B. van de Wiel, Richard A. Scolyer, H.V. van Thienen, Henk Mallo, Maria Gonzalez, L. Landman, A. Torres Acosta, Lindsay G. Grijpink-Ongering, John B.A.G. Haanen, Alexander C. J. van Akkooi, Georgina V. Long, Christian U. Blank
20231

About Henk Mallo

Henk Mallo is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Cancer Research, having authored 24 papers that have together received 449 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Renal cell carcinoma treatment (6 papers), CAR-T cell therapy research (6 papers), Immunotherapy and Immune Responses (4 papers), Melanoma and MAPK Pathways (4 papers), Cancer Genomics and Diagnostics (3 papers), Protein Degradation and Inhibitors (2 papers) and Cutaneous Melanoma Detection and Management (2 papers). The work is most often cited by research in Oncology (176 citations), Immunology (124 citations), Pulmonary and Respiratory Medicine (152 citations), Ophthalmology (29 citations) and Cancer Research (41 citations). Henk Mallo has collaborated with scholars based in Netherlands, Australia and Sweden. Frequent co-authors include John B.A.G. Haanen, Gijsbert C. de Gast, Astrid A.M. van der Veldt, Epie Boven, Helgi H. Helgason, Axel Bex, Alfons J.M. van den Eertwegh, Johannes Berkhof, Simon Horenblas and Christian U. Blank. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Cancer Immunology Immunotherapy and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georgia GomatouBreakdown of academic impact, for papers by Davide BossoBreakdown of academic impact, for papers by Amandine QuivyBreakdown of academic impact, for papers by Deirdre KellyBreakdown of academic impact, for papers by Nethanel AsherBreakdown of academic impact, for papers by Mazhar AjazBreakdown of academic impact, for papers by Annelieke E.C.A.B. WillemsenBreakdown of academic impact, for papers by J.B.A.G. HaanenBreakdown of academic impact, for papers by V. Guillem PortaBreakdown of academic impact, for papers by Depei Huang